FDA panel backs bladder cancer test:
This article was originally published in Clinica
Martitech, of Newton, Massachusetts, could soon be marketing its bladder cancer test for patients who have symptoms or are at risk of the disease, if the FDA takes the advice of its advisory panel. Last week, the panel recommended that the NMP22 test kit, which is already approved in the US for monitoring bladder cancer recurrence, should also be used on undiagnosed patients with symptoms or on those at high risk, providing there is an increase in the cut-off value and labelling that suggests it should be used with the current standard of care.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.